Cellectis (CLLS) Cash & Equivalents Growth (1y) (2014 - 2026)
Powered by 
Analysis
Cellectis (CLLS) Cash & Equivalents Growth (1y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 23.56% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 23.05% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 71.81% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 34.71% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 84.98% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 53.39% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 28.50% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -57.58% |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | -40.49% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -40.49% |
| Mar 31, 2026 | -72.70% |
| Dec 31, 2025 | -57.05% |
| Sep 30, 2025 | -67.16% |
| Jun 30, 2025 | -59.87% |
| Mar 31, 2025 | 3.79% |
| Dec 31, 2024 | 4.79% |
| Sep 30, 2024 | 136.18% |
| Jun 30, 2024 | 76.62% |
| Mar 31, 2024 | 47.24% |
| Dec 31, 2023 | 46.66% |
| Sep 30, 2023 | -31.02% |
| Jun 30, 2023 | -34.81% |
| Mar 31, 2023 | -46.07% |
| Dec 31, 2022 | -49.79% |
| Sep 30, 2022 | -53.66% |
| Jun 30, 2022 | -47.85% |
| Mar 31, 2022 | -25.35% |
| Dec 31, 2021 | -23.02% |
| Sep 30, 2021 | -19.25% |